跳至主要内容
临床试验/NCT03088280
NCT03088280Unknown4 期

Prospective Randomized Study to Evaluate the Efficacy and Safety of Rabbit Antithymocyte Globulin 3mg/kg vs. 6mg/kg in Kidney Transplant Patients Under Steroid-free and CNI Minimization Maintenance Immunosuppressive Regimen

Hospital Geral de Fortaleza1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2015年6月30日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
入组人数
200
试验地点
1
主要终点
Acute rejection

研究概览

简要总结

Single-center, prospective, randomized, open-label clinical trial to evaluate the 1-year efficacy and safety of rATG 3mg/kg compared to 6mg/kg in low to moderate immunological risk patients receiving low exposure tacrolimus plus everolimus (EVL) in a steroid-free protocol.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Sequential
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Primary kidney transplant recipients, adults

排除标准

  • PRA > 50%
  • DSA > 1500 MFI
  • Retransplantation
  • Patients who are planning to receive mycophenolate instead of everolimus
  • Patients who have planning for follow-up in another center

研究组 & 干预措施

3mg/kg Group

Experimental

Patients will received Thymoglobuline 3mg/Kg (reduced dose)

干预措施: Thymoglobulin (Drug)

6mg/kg Group

Active Comparator

Patients will received Thymoglobuline 6mg/Kg (standard dose)

干预措施: Thymoglobulin (Drug)

结局指标

主要结局

Acute rejection

时间窗: 1 year

Biopsy proven and all treated acute rejection episodes

次要结局

  • Infection(1 year)

研究者

申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Tainá Veras de Sandes Freitas

MD PhD

Hospital Geral de Fortaleza

研究点 (1)

Loading locations...

相似试验